Biohaven Ltd. (NYSE:BHVN) Director John W. Childs Buys 32,700 Shares

Biohaven Ltd. (NYSE:BHVN) Director John W. Childs purchased 32,700 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, with a total value of $996,369.00. Following the transaction, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Biohaven Trading Down 1.2 %

Shares of BHVN stock opened at $30.98 on Thursday. The firm has a fifty day simple moving average of $38.07 and a 200-day simple moving average of $42.66. The company has a market capitalization of $3.13 billion, a PE ratio of -3.31 and a beta of 1.27. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). Equities research analysts predict that Biohaven Ltd. will post -8.9 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a report on Tuesday. TD Cowen upped their price target on Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. JPMorgan Chase & Co. dropped their target price on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Biohaven in a report on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price target on the stock. Fourteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $62.77.

Institutional Investors Weigh In On Biohaven

A number of hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. raised its position in shares of Biohaven by 745.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock valued at $74,969,000 after purchasing an additional 1,322,922 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Biohaven by 144.5% in the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company’s stock valued at $73,922,000 after acquiring an additional 1,169,721 shares in the last quarter. Norges Bank bought a new position in Biohaven during the 4th quarter valued at $33,711,000. Farallon Capital Management LLC grew its holdings in Biohaven by 21.6% during the 4th quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company’s stock worth $165,392,000 after acquiring an additional 785,578 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Biohaven by 12.1% in the 4th quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company’s stock worth $260,735,000 after purchasing an additional 756,032 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.